509.1

-0.08%↓

SANES

8.421

-1.39%↓

SAF

283.1

-1.67%↓

BBVA

16.05

-0.96%↓

BNP

78.57

-2.36%↓

509.1

-0.08%↓

SANES

8.421

-1.39%↓

SAF

283.1

-1.67%↓

BBVA

16.05

-0.96%↓

BNP

78.57

-2.36%↓

509.1

-0.08%↓

SANES

8.421

-1.39%↓

SAF

283.1

-1.67%↓

BBVA

16.05

-0.96%↓

BNP

78.57

-2.36%↓

509.1

-0.08%↓

SANES

8.421

-1.39%↓

SAF

283.1

-1.67%↓

BBVA

16.05

-0.96%↓

BNP

78.57

-2.36%↓

509.1

-0.08%↓

SANES

8.421

-1.39%↓

SAF

283.1

-1.67%↓

BBVA

16.05

-0.96%↓

BNP

78.57

-2.36%↓

Home・Akcijų sąrašas・AB Science SA

AB Science SA

Atidarymo kaina

1.23 -1.76

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.18

Max

1.26

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-3.4M
Pardavimai	512K
Pelno marža	-656.641
Darbuotojai	28
EBITDA	-1.9M

Dividendai
By Dow Jones
Kitas uždarbis	2025-09-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	76M
Ankstesnė atidarymo kaina	2.99
Ankstesnė uždarymo kaina	1.23

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.426 / 1.448 Palaikymas ir pasipriešinimas

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-16 17:03; UTC

Pagrindinės rinkos jėgos

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

2025-09-16 16:49; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

GD Culture Shares Drop After Deal for Pallas Capital

2025-09-16 16:11; UTC

Pagrindinės rinkos jėgos

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

2025-09-16 23:40; UTC

Rinkos pokalbiai

Nikkei May Decline as Yen Strengthens -- Market Talk

2025-09-16 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

2025-09-16 23:20; UTC

Rinkos pokalbiai

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

2025-09-16 21:10; UTC

Įsigijimai, susijungimai, perėmimai

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

2025-09-16 20:51; UTC

Rinkos pokalbiai

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

2025-09-16 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-09-16 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2025-09-16 20:25; UTC

Uždarbis

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

2025-09-16 20:24; UTC

Uždarbis

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

2025-09-16 19:19; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

2025-09-16 18:52; UTC

Rinkos pokalbiai

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

2025-09-16 18:44; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-16 18:44; UTC

Rinkos pokalbiai

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

2025-09-16 18:40; UTC

Įsigijimai, susijungimai, perėmimai

Details Emerge on U.S.-China TikTok Deal -- WSJ

2025-09-16 18:38; UTC

Rinkos pokalbiai

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

2025-09-16 18:19; UTC

Rinkos pokalbiai

Gold Settles at New High Ahead of Fed Decision -- Market Talk

2025-09-16 18:01; UTC

Rinkos pokalbiai

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

2025-09-16 17:34; UTC

Rinkos pokalbiai

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

2025-09-16 16:53; UTC

Uždarbis

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

2025-09-16 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2025-09-16 16:15; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Global Commodities Roundup: Market Talk

2025-09-16 16:09; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Global Energy Roundup: Market Talk

2025-09-16 16:09; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

2025-09-16 15:35; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-16 15:35; UTC

Rinkos pokalbiai

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

2025-09-16 15:22; UTC

Rinkos pokalbiai

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

2025-09-16 15:21; UTC

Rinkos pokalbiai

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Akcijų palyginimas

Kainos pokytis

AB Science SA Prognozė

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.